| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Angiogenesis serves a crucial role in tumor growth. Bevacizumab inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects in oral squamous cell carcinoma (OSCC) patients. Generally, local injections of antitumor agents decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. The present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining and apoptosis assays. Compared with controls, peritumoral bevacizumab injections significantly inhibited tumor growth in OSCC xenografts and treatment with bevacizumab significantly reduced microvessel density and increased level of tumor cell apoptosis. These results support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.
|
